Formulation: 2 mg of docetaxel contained in TBS-buffered TPGS and poloxanlene polymeric nanoparticles containing trehalose
Shelf life (days): 1095
Notes: Docetaxel polymeric nanoparticles (PNPs) are nanoparticles composed of tocofersolan (TPGS; Item No. 34661), poloxanlene, trehalose (Item No. 20517), and TBS that encapsulate docetaxel (Item No. 11637) and are 15 to 20 nm in size as determined by dynamic light scattering (DLS). PNP formulations are a lipid-based drug delivery (LBDD) system that improve drug bioavailability and solubility, protect the cargo from degradation or metabolism, control drug release, and help lower the biological impacts observed by DMSO and other organic solvents.{68570,68571} Docetaxel is a microtubule-stabilizing agent and a semisynthetic derivative of paclitaxel (Item No. 10461).{20977} Formulations containing docetaxel have been used in the treatment of head and neck, breast, and non-small cell lung cancer, gastric adenocarcinoma, and castration-resistant prostate cancer. Before use, reconstitute the docetaxel PNPs in 1 ml of deionized water and dilute the reconstituted docetaxel PNPs prior to performing biological experiments.
English
Deutsch
